Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01906060
Other study ID # 2013-0151
Secondary ID
Status Completed
Phase Phase 4
First received July 18, 2013
Last updated June 28, 2016
Start date July 2013
Est. completion date June 2016

Study information

Verified date June 2016
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority Switzerland: Swissmedic
Study type Interventional

Clinical Trial Summary

The disposable Air-Q self-inflating laryngeal intubation mask (Air-Q, Mercury Medical, Clearwater, FL, USA) is an extra-glottic airway device which enables blind intubation with a tracheal tube. This intubating laryngeal airway device (ILA) is already commercially available and worldwide certificated (CE 0482), but data about the success rates of blind intubation via this device in adult patients are lacking. Success rates of blind intubations with the non-self-inflating device range between 57 and 97%.

Although the self-inflating disposable Air-Q device is certified for blind intubation, the success rate and rate of adverse events associated with this procedure have not been published so far. In a study comparing adverse events of conventional intubation with blind intubation via a different supra-glottic airway device (ILMA) the rates of sore throat and cough were comparable in both groups and were reported in 10-17% of the patients. In a pilot study using the non-self-inflating Air-Q for blind intubation in 19 patients, 10% reported dysphagia and one patient had a bilateral lingual nerve injury which was self-limited. One study using the self-pressurised disposable Air-Q for ventilation of children showed broncho- or laryngospasm in 3% and mucosal damage such as blood stained ILA or sore throat were reported in 1%.

This data suggests that the rate of adverse events using the Air-Q supra-glottic device are comparable to other devices such as LMA.

- Trial with medical device


Recruitment information / eligibility

Status Completed
Enrollment 1000
Est. completion date June 2016
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 85 Years
Eligibility Inclusion criteria:

- elective surgery requiring tracheal intubation using an oral tracheal tube

- anticipated extubation in the operating room

- American Society of Anaesthesiologist Physical Status 1-3

- age = 18 years and = 85 years

- oral and written informed consent

- weight = 100kg (according to the product description)

- ability to understand the study information

Exclusion criteria:

- pharyngeal, laryngeal or tracheal pathology, including tracheostomy

- mouth opening < 2.5 cm

- any form of airway infection such as upper-respiratory tract infection, pneumonia or suspected tuberculosis

- any disease that might impair the power of judgement (psychiatric disease, dementia)

- indicated rapid sequence induction which is a standard when high risk for regurgitation and/or aspiration is present

- the subject must not be involved in any other clinical trial during the course of this trial, nor within a period of 30 days prior to its beginning or 30 days after its completion

- pregnancy

- breast feeding

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Elective Surgery Requiring Tracheal Intubation Using an Oral Tracheal Tube

Intervention

Device:
Air-Q Intubation Laryngeal Mask
Patients will be intubated using the Air-Q Laryngeal Mask.

Locations

Country Name City State
Poland Medical University Lodz Lodz
Switzerland KantonsSpital Winterthur Winterthur
Switzerland University Hospital Zurich, Institute of Anaesthesiology Zurich ZH

Sponsors (1)

Lead Sponsor Collaborator
University of Zurich

Countries where clinical trial is conducted

Poland,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Success rate of blind intubation via the disposable Air-Q self-inflating laryngeal intubation mask. Success is defined as placement of a tracheal tube into trachea with no more than two insertion attempts. 300 seconds Yes
Secondary Time for insertion of the Air-Q laryngeal mask defined as time beginning at the moment the ILA enters the mouth until the appearance of the capnography waveform 300 seconds No
Secondary Time for insertion of the tube defined as the time beginning at the moment of insertion of the tube through the laryngeal mask until the appearance of the capnography waveform 300 seconds No
Secondary First attempt rate and second attempt rate 300 seconds No
Secondary Time for removal of the Air-Q ILA device after successful intubation 500 seconds No
Secondary Rate of misplacement of the ILA 300 seconds Yes
Secondary Rate of misplacement of the tube 500 seconds Yes
Secondary risk factors of insertion failures 500 seconds Yes
Secondary Rate of airway injuries 5 hours No
Secondary Tightness during leak test before relaxation 300 seconds No
Secondary Tightness during leak test after relaxation 300 seconds No
Secondary Maximum drop of saturation during airway management 500 seconds Yes
Secondary Rate of adverse events including, but not limited to suspicion of aspiration or regurgitation (gastric fluid in the ventilation tube or hypopharynx), bronchospasm, airway obstruction, coughing, dental-, tongue-, lip- pharyngeal or laryngeal trauma 5 hours Yes
Secondary Rate of necessity of alternative airway device 500 seconds No
Secondary Rate of blood stained devices after removal of the ILA 500 seconds No
Secondary Postoperative coughing after 2 hours and the next morning 24 hours No
Secondary Postoperative hoarseness after 2 hours and the next morning 24 hours No